Iclepertin for cognition and daily function in schizophrenia: CONNEX-2
About this title
Read the official source — NCT04846881Researchers compared Iclepertin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Understand this study
What did researchers investigate?
Researchers compared Iclepertin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- Bellflower and 126 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 611
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Argentina, ...
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT04846881
- Official title
Show the full official title
A Phase III Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Examine the Efficacy and Safety of Iclepertin Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-2)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Bellflower, United States · Costa Mesa, United States · Long Beach, United States
112 more locations
- Los Angeles, United States
- Orange, United States
- Torrance, United States
- New Haven, United States
- Hialeah, United States
- Miami, United States
- West Palm Beach, United States
- Chicago, United States
- Baltimore, United States
- St Louis, United States
- Cedarhurst, United States
- New York, United States
- Independence, United States
- Dallas, United States
- Fort Worth, United States
- Salem, United States
- Bellevue, United States
- CABA, Argentina
- Córdoba, Argentina
- La Plata, Argentina
- Mendoza, Argentina
- Rosario, Argentina
- Rio de Janeiro, Brazil
- São Bernardo do Campo, Brazil
- São Paulo, Brazil
- Santiago, Chile
- Segunda Región, Chile
- Rijeka, Croatia
- Zagreb, Croatia
- Bordeaux, France
- Clermont-Ferrand, France
- Créteil, France
- Le Chesnay-Rocquencourt, France
- Lille, France
- Montpellier, France
- Nantes, France
- Nice, France
- Nîmes, France
- Rennes, France
- Rouffach, France
- Saint-Priest-en-Jarez, France
- Budapest, Hungary
- Debrecen, Hungary
- Pécs, Hungary
- Aichi, Toyoake, Japan
- Aichi, Toyota, Japan
- Chiba, Chiba, Japan
- Fukuoka, Chikugo, Japan
- Fukuoka, Fukuoka, Japan
- Fukuoka, Kurume, Japan
- Gumma, Kiryu, Japan
- Hokkaido, Sapporo, Japan
- Hyogo, Kobe, Japan
- Ishikwa, Kahoku-gun, Japan
- Kanagawa, Kawasaki, Japan
- Kanagawa, Yokohama, Japan
- Kumamoto, Kumamoto, Japan
- Kumamoto, Yatsushiro, Japan
- Nagano, Suwa, Japan
- Nara, Kashihara, Japan
- Okinawa, Ginowan, Japan
- Osaka, Osaka, Japan
- Saga, Karatsu, Japan
- Saga, Tosu, Japan
- Tokyo, Adachi-ku, Japan
- Tokyo, Bunkyo-ku, Japan
- Tokyo, Kita-ku, Japan
- Tokyo, Minato-ku, Japan
- Tokyo, Ota-ku, Japan
- Tokyo, Shibuya-ku, Japan
- Tokyo, Shinjuku-ku, Japan
- Toyama, Nanto, Japan
- Ipoh, Malaysia
- Kuala Lumpur, Malaysia
- Kuching, Malaysia
- Seremban, Negeri Sembilan, Malaysia
- Groningen, Netherlands
- Maastricht, Netherlands
- Bełchatów, Poland
- Bialystok, Poland
- Gdansk, Poland
- Gliwice, Poland
- Gmina Świecie, Poland
- Szczecin, Poland
- Zabrze, Poland
- Bucharest, Romania
- Sibiu, Romania
- Belgrade, Serbia
- Novi Kneževac, Serbia
- Novi Sad, Serbia
- Singapore, Singapore
- Bojnice, Slovakia
- Košice, Slovakia
- Rimavská Sobota, Slovakia
- Busan, South Korea
- Daegu, South Korea
- Incheon, South Korea
- Jeonju, South Korea
- Seoul, South Korea
- Barcelona, Spain
- Collado de Villalba, Spain
- Córdoba, Spain
- Getafe, Spain
- Majadahonda, Spain
- Palma, Spain
- Salamanca, Spain
- Sant Boi de Llobregat, Spain
- Seville, Spain
- Valencia, Spain
- Vigo, Spain
- Zamora, Spain
- Nove, Ukraine
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Iclepertin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Who is behind this study?
The study sponsor is Boehringer Ingelheim.
Did this study involve medication?
Yes. The study involved medication, including Iclepertin and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
